52w high/low | ₹1465 / ₹831 |
P/E ratio | 59.02 |
Dividend | 1.82 |
ROE | 18.55 |
ROCE | 24.87 |
Face value | 10 |
Book value | ₹90.46Cr |
Market capital | ₹5,242.68Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Thyrocare Technologies Limited was incorporated in the year January 28, 2000. The company is one of the leading pan-India diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases. As of 31 March 2021, the company offered 279 tests and 79 profiles of tests to detect a number of disorders, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility and various infectious diseases. The company's profiles of tests include 51 profiles of tests administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests. The company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs). The company currently operates 9 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions. Nueclear Healthcare Limited (NHL), the wholly owned subsidiary of Thyrocare Technologies, is engaged in PET-CT Scan imaging diagnostic business. NHL currently has 14 operating PET-CT scanners in 12 imaging centers: two in Navi Mumbai, two in New Delhi, one each in Hyderabad, Surat, Vadodara, Raipur, Jaipur, Mumbai Aurangabad, Nashik, Bangalore and Coimbatore.